BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Neuron23 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Neuron23's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06680830-1691@assetmemo.bio
DTSTAMP:20261121T005331Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:NEU-411: Phase 2 readout est. (NCT06680830)
DESCRIPTION:NEU-411\, phase 2\, Parkinson's Disease.\nStudy: A Phase 2 Stud
 y and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Par
 ticipants With Early Parkinson's Disease\nEstimated primary completion: De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/neu-411#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0668
 0830
URL:https://assetmemo.bio/drug/neu-411#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
